{'fraction_non_alphanumeric': 0.021568627450980392, 'fraction_numerical': 0.0, 'mean_word_length': 6.097222222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rectal NSAIDs and selective pancreatic stenting significantly reduces acute pancreatitis in normal risk ERCP

Acute pancreatitis remains one of the most feared complications from endoscopic retrograde cholangiopancreatography (ERCP). Evidence in high‐risk cases suggests that a combination of Non steroidal anti inflammatory drugs (NSAID) and selective pancreatic stenting reduces the risk of post ERCP pancreatitis (PEP). However, few studies have investigated whether this is beneficial for normal risk ERCP.